Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zintus HD Study: Low-dose zinc therapy in hemodialysis patients with hypozincemia
jRCTs051260148Recruiting
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of zinc acetate in zinc deficiency, chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms). Primary endpoint: Serum zinc level at 12 weeks after randomization. Started Aug 2026; status: recruiting.
02
Drugs
zinc acetate
03
Conditions
zinc deficiencychronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCTs051260148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260148.